On July 15, 2025, Compass Pathways (CMPS, Financial) continues to hold the confidence of HC Wainwright & Co. The firm, represented by analyst Patrick Trucchio, reiterated its 'Buy' rating for the renowned firm, emphasizing its positive outlook for the company.
The price target for Compass Pathways (CMPS, Financial) remains unchanged at $45.00 USD, as confirmed by HC Wainwright & Co. This stability in the price target reflects consistent performance expectations from the company's strategic initiatives and market conditions.
Investors looking at Compass Pathways (CMPS, Financial) can take note of HC Wainwright & Co.'s maintained price target and rating, indicating a sustained belief in the stock’s potential growth and value in the current market landscape. The steady outlook suggests that Compass Pathways continues to be a compelling option for those seeking investment opportunities in the healthcare sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 9 analysts, the average target price for Compass Pathways PLC (CMPS, Financial) is $15.78 with a high estimate of $45.00 and a low estimate of $6.00. The average target implies an upside of 336.45% from the current price of $3.62. More detailed estimate data can be found on the Compass Pathways PLC (CMPS) Forecast page.
Based on the consensus recommendation from 9 brokerage firms, Compass Pathways PLC's (CMPS, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
